The adequacy of these studies in quantifying the burden of HZ and PHN was critically assessed. RESULTS: Only a small number of published prospective studies (n = 6) designed to investigate the impact of HZ or PHN from patients' perspectives were identifi ed; one of which was conducted in the UK. The HRQoL burden associated with HZ and PHN was highlighted in the studies reviewed albeit a number of key points were noted. First, the burden of HZ and PHN has not been compared to HRQoL estimates for the general population or to those with comparable acute or chronic conditions, thereby making interpretation diffi cult. Furthermore, studies conducted to date have not accounted for the variations in pain and HRQOL burden at different stages of HZ presentation. Finally, from the studies reviewed, the pain experienced by patients with HZ and PHN is managed with a wide variety of products. However, until now no formal assessment of patient satisfaction with these products has been conducted. CONCLUSIONS: Although it is known that HZ and PHN can have a negative impact on HRQOL, limitations in previous research can be noted. In order to address these concerns, a large-scale UK-based prospective study is currently being conducted. OBJECTIVES: Incidence and severity of herpes zoster (HZ) increase with age. Postherpetic neuralgia (PHN) is its most common complication. The study objective was to assess the impact of HZ and PHN on daily life and quality of life (QoL) as perceived by the patient. METHODS: A 12-month, longitudinal, observational study conducted on patients aged ≥50 years with acute HZ (eruptive phase), included by a representative sample of 644 French general practitioners (GP) between June 2007 and June 2008. Demographic and disease characteristics and treatment procedures were collected by the GP at the inclusion and at 3, 6 and 12 months. PHN and QoL assessments were performed by telephone interview of patients, at regular time points over 12 months, using comprehensive and validated questionnaires. RESULTS: a total of 1358 patients met the selection criteria and 1032 completed the follow-up. Mean age was 67.7 ± 10.7 years (62.2% female). Mean time between rash onset and HZ diagnosis was 2.6 ± 3.0 days. Most patients (94.1%) were treated with antiviral drugs. PHN prevalence at inclusion, 3, 6, and 12 months was 79.6%, 11.6%, 8.5%, and 6.6% respectively. Mean Zoster Brief Pain Inventory (ZBPI) interference score (range = 0-10 worse) at inclusion, 3, 6 and 12 months was 3.1 ± 2.4, 2.9 ± 2.3, 2.5 ± 2.1, 2.7 ± 2.3 respectively, with main impact on general activity, sleep and mood. Throughout the 12-month study period, patients with persistent PHN presented lower scores on the physical (e.g. at 12 month: 39.7 ± 13.7) and mental (43.6 ± 11.3) component summaries of the 12-item short-form health survey (SF-12) than the patients without PHN, respectively 46.0 ± 10.6 and 47.8 ± 10.5. Moreover, univariate analysis found that among predictive factors at inclusion for PHN were a ZBPI score ≥5 (P < 0.001) and a low SF-12 physical component summary (P < 0.001). CONCLUSIONS: This large cohort study confi rms the HZ and PHN impact on daily life and quality of life, in spite of prompt diagnosis and antiviral treatment.
PIN66 EVALUATION OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS RECEIVING ANTIRETROVIRAL THERAPY IN MAITAMA DISTRICT HOSPITAL, ABUJA NIGERIA
Agu KA 1 , Okojie O 2 , Omonaiye O 1 , Oqua D 1 , King RC 3 , Onuoha C 1 , Muhammadu I 1 , Iyaji PG 1 1 Howard University PACE Center, Abuja, FCT, Nigeria; 2 University of Benin, Benin, Edo, Nigeria; 3 Howard University PACE Center, NW, WA, USA OBJECTIVES: HIV-infected patients demonstrate a health-related quality of life (HRQoL) lower than that of the general population. The goals of antiretroviral therapy (ART) include the improvement of HRQOL in addition to the reduction of symptoms, suppression of the virus, and enhancement of survival. The study evaluated HRQoL of HIV-infected patients at months 0 and 6 of receiving ART; and compared the HRQoL index of male and female participants. METHODS: The HRQoL of a cohort of 150 HIV-infected patients was evaluated at months 0 and 6 of receiving ART using SF-36 health survey form. Wilcoxon's signed ranks test was used to compare the HRQoL index between two groups of data. All reported P values were 2-sided, and P < 0.05 was used to determine statistical signifi cance. RESULTS: The mean age of the 150 patients at initiation of antiretroviral treatment was 34.30 (95% CI, 32.96-35.64) years; and 59.3% were females. At 6 months follow-up, 118 (78.7%) ART patients who met the 6 th month medication refi ll appointment were evaluated for HRQoL. Before commencing ART, the mean HRQoL of participants was 71.22 (95%CI, 68.00-74.44) which increased signifi cantly to 90.83 (95%CI, ) at 6 months follow up on ART (P < 0.05). The change across all the HRQoL domains in the SF-36 instrument was also statistically signifi cant (P < 0.05) except for the domains of role limitation due to emotional problems, social functioning and pain (p > 0.05). Difference in the HRQoL index of male and female gender at months 0 and 6 was not statistically signifi cant (p > 0.05). CONCLUSIONS: There was a signifi cant improvement in the mean HRQoL of the participants after 6 months of ART; the difference between HRQoL index of male and female participants was not signifi cant. Routine evaluation of HRQoL in clinical practice is highly recommended as long-term outcome may be different.
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PIN67 MODELING G-DRG REVENUE WHEN HOSPITALIZATION DURATION FROM CLINICAL TRIALS IS AVAILABLE: THE CASE OF DORIPENEM VERSUS IMIPENEM IN TREATING VENTILATOR-ASSOCIATED PNEUMONIA (VAP) IN GERMANY
De Cock E 1 , Gast C 2 , Berndt K 3 , Kubitz N 3 1 United BioSource Corporation, Barcelona, Spain; 2 Axio Research Acquisition Co. LLC, Seattle, WA, USA, 3 Janssen-Cilag GmbH, Neuss, Germany OBJECTIVES: Since the introduction of G-DRGs, hospitals have become increasingly concerned about impact of changes in clinical practice on hospital costs and revenue. We developed an algorithm to estimate expected G-DRG payment by drug, when length-of-stay (LOS) data from clinical trials are available. We compared results with a scenario where only median values by trial arm are available. METHODS: G-DRG attribution is driven by MV duration and intensive care severity score. From a Phase III trial comparing doripenem and imipenem (DORI-10), we determined nine categories of MV duration (ranges based on MV hours resulting in higher-paying G-DRGs). Using the Muenster Webgrouper, we obtained G-DRG weights when simultaneously varying MV duration and intensive care severity (15 levels) for four clinical profi les. For the nine categories and by drug, we obtained percentage patients per group and median LOS by type of ward using. Per category, the appropriate G-DRG weight was selected based on: chosen profi le, total MV duration, intensive care severity, and total LOS. Using distribution of patients by category derived from DORI-10, a weighted G-DRG was calculated for each arm, and multiplied by the 2010 base value to yield expected G-DRG payment. RESULTS: G-DRG revenue ranged from c2,578 to c8,575 (across 4 scenarios) to c136,164 for MV ≥ 1800 hours. Using trial-based median LOS values, expected G-DRG revenue is c30,397 (all scenarios), with no difference in G-DRG revenue in both trial arms. When using the categories approach, expected revenue reduction when using doripenem instead of imipenem ranged from c2,084 to c2,451. CONCLUSIONS: A G-DRG revenue analysis helps to better understand net impact of introducing a new drug on a hospital's budget. When LOS data (including MV) vary by drug and data from clinical studies are available, a classifi cation approach enables more refi ned G-DRG revenue estimates as opposed to using median values by drug.
PIN68 EFFECT OF THE ANTIBIOTICS USE MONITORING PROGRAM FOR THE ACUTE UPPER-RESPIRATORY INFECTIONS DISEASE IN KOREAN CLINICS
Choi SE 1 , Park KH 1 , Lim EA 1 , Kim SK 2 1 Seoul National University, Seoul, South Korea; 2 Health Insurance Review & Assessment Agency, Seoul, South Korea OBJECTIVES: Overuse of antibiotics has been focused for the public health and pharmaceutical expenditure in Korea. National Health Insurance introduced the antibiotics use monitoring program in 2002. This program includes a monitoring the antibiotics prescription rates of medical institutes, a feedback to prescribers, and a report to the public via website. This study aims to evaluate the impact of this program on the antibiotics prescription rates for the acute upper-respiratory infections (URI) in Korea. METHODS: We assessed the antibiotics prescription rates for the acute URI (J00-J06) of individual medical institutes from 2002 to 2008. Data was extracted from NHI outpatient's claims database and the fi rst quarter data of each year were selected to avoid seasonal variation. To evaluate the effect of program, we assumed the early change of prescription rate during 2002-2003 as a baseline, and compared it with every year variations of the prescription rate for 2004-2008. Generalized Estimation Equation (GEE) model was constructed to investigate the changes in antibiotics prescription. RESULTS: Data included about 49 million claims from 13,211 clinics (94.5% of all acute URI claims and 70.5% of all clinics in 2008). Prescription rate declined from 72.8% to 55.1% during 2002-2008. The analysis showed that the antibiotics use monitoring program reduced 6.11% of antibiotics prescription rate per clinic annually (OR: 0.62, 95% CI: 0.61, 0.64, P < 0.0001). The reduced antibiotics prescription estimate was average 4.5 million a year. CONCLUSIONS: After monitoring system introduced, the antibiotics prescription rates for acute URI patients have continuously decreased in the clinics.
